Cancer cell killing by target antigen engagement with engineered complementary intracellular antibody single domains fused to pro-caspase3
<p>Many tumour causing proteins, such as those expressed after chromosomal translocations or from point mutations, are intracellular and are not enzymes <em>per se</em> amenable to conventional drug targeting. We previously demonstrated an approach (<u>A</u>ntibody-anti...
| Príomhchruthaitheoirí: | , , |
|---|---|
| Formáid: | Journal article |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
Nature Research
2019
|